Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Molecular Oncology
|
February 4, 2025
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models
Alessia Anastasia, Laura Formenti, Paola Ostano, et al.
Cancer Chemotherapy and Pharmacology
|
September 30, 2021
Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement
Annalisa Condorelli, Cristina Matteo, Salvatore Leotta, et al.
Targeted Oncology
|
December 28, 2020
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 11, 2018
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin
Umberto Capasso Palmiero, Lavinia Morosi, Ezia Bello, et al.
International Journal of Nanomedicine
|
January 23, 2024
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
Jesse Demuytere, Charlotte Carlier, Leen Van de Sande, et al.
British Journal of Cancer
|
February 13, 2020
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
Ezia Bello, Silvia Brich, Ilaria Craparotta, et al.
British Journal of Cancer
|
August 15, 2019
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
Ezia Bello, Silvia Brich, Ilaria Craparotta, et al.
Iscience
|
January 16, 2026
Intermittent fasting enhances cisplatin-metformin efficacy in therapy-resistant ovarian cancer PDXs
Elena Capellini, Ludovica Perotti, Federica Guffanti, et al.
Oncoimmunology
|
August 4, 2023
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells
Massimo Russo, Nicolò Panini, Paola Fabbrizio, et al.
Cancer
|
August 5, 2020
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
Federica Grosso, Lorenzo D'Ambrosio, Massimo Zucchetti, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Molecular Oncology
|
February 4, 2025
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models
Alessia Anastasia, Laura Formenti, Paola Ostano, et al.
Cancer Chemotherapy and Pharmacology
|
September 30, 2021
Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement
Annalisa Condorelli, Cristina Matteo, Salvatore Leotta, et al.
Targeted Oncology
|
December 28, 2020
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 11, 2018
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin
Umberto Capasso Palmiero, Lavinia Morosi, Ezia Bello, et al.
International Journal of Nanomedicine
|
January 23, 2024
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
Jesse Demuytere, Charlotte Carlier, Leen Van de Sande, et al.
British Journal of Cancer
|
February 13, 2020
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
Ezia Bello, Silvia Brich, Ilaria Craparotta, et al.
British Journal of Cancer
|
August 15, 2019
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
Ezia Bello, Silvia Brich, Ilaria Craparotta, et al.
Iscience
|
January 16, 2026
Intermittent fasting enhances cisplatin-metformin efficacy in therapy-resistant ovarian cancer PDXs
Elena Capellini, Ludovica Perotti, Federica Guffanti, et al.
Oncoimmunology
|
August 4, 2023
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells
Massimo Russo, Nicolò Panini, Paola Fabbrizio, et al.
Cancer
|
August 5, 2020
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
Federica Grosso, Lorenzo D'Ambrosio, Massimo Zucchetti, et al.
Page
of 3